Percentage of Her2 positive cells in immunohistochemistry-equivocal (2+) invasive breast cancer and its significance as a predictive value for the amplification status

被引：0
|
作者：
Marras, V. [1 ]
Satta, G. [1 ]
Fedeli, M. A. [1 ]
Trombetta, M. [1 ]
Lako, K. [1 ]
Meloni, M. [1 ]
Fara, A. M. [1 ]
Camboni, A. C. [1 ]
Doneddu, V. [1 ]
Manca, A. [1 ]
Tanda, F. [1 ]
机构：
[1] AOU Sassari, UO Anat Patol, Sassari, Italy
来源：
VIRCHOWS ARCHIV | 2017年 / 471卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
PS-01-034
引用
收藏
页码：S58 / S58
页数：1
相关论文
共 50 条
  • [31] Percentage of HER2 immunohistochemistry complete membrane staining is not significantly associated with response to neoadjuvant therapy in HER2 positive breast cancer
    Li, Xiaoxian
    Zhao, Jing
    Zhang, Chao
    Li, Zaibo
    MODERN PATHOLOGY, 2019, 32
  • [32] Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting
    Wu, Ziping
    Xu, Shuguang
    Zhou, Liheng
    Yin, Wenjin
    Lin, Yanpin
    Du, Yueyao
    Wang, Yaohui
    Jiang, Yiwei
    Yin, Kai
    Zhang, Jie
    Lu, Jinsong
    ONCOTARGETS AND THERAPY, 2018, 11 : 801 - 808
  • [33] Percentage of HER2 immunohistochemistry complete membrane staining is not significantly associated with response to neoadjuvant therapy in HER2 positive breast cancer
    Li, Xiaoxian
    Zhao, Jing
    Zhang, Chao
    Li, Zaibo
    LABORATORY INVESTIGATION, 2019, 99
  • [34] The frequency of HER2 amplification and the percentage of membrane staining in HER2 2+invasive carcinomas of the breast Reply
    Polonia, Antonio
    Canelas, Carolina
    Caramelo, Ana
    VIRCHOWS ARCHIV, 2022, 481 (02) : 329 - 330
  • [35] Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: A study at a tertiary cancer center
    Murthy, Sudha S.
    Sandhya, D. G.
    Ahmed, Faiq
    Goud, K. Iravathy
    Dayal, Monal
    Suseela, K.
    Rajappa, Senthil J.
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2011, 54 (03) : 532 - 538
  • [36] Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer
    Albina Stocker
    Andreas Trojan
    Constanze Elfgen
    Marie-Louis Hilbers
    Linda Moskovszky
    Zsuzsanna Varga
    Breast Cancer Research and Treatment, 2020, 183 : 311 - 319
  • [37] Biological analysis of HER2 equivocal (2+) cases in primary breast cancer.
    Nishimura, Reiki
    Osako, Tomofumi
    Okumura, Yasuhiro
    Nakano, Masahiro
    Fujisue, Mamiko
    Arima, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Impact of the 2018 ASCO/CAP HER2 Guideline Updates on HER2 Assessment in Breast Cancer with HER2 Immunohistochemistry Equivocal Results
    Wen, Hannah
    Ventura, Katia
    Xu, Jin
    Ross, Dara
    Dang, Chau
    Robson, Mark
    Norton, Larry
    Morrow, Monica
    Brogi, Edi
    LABORATORY INVESTIGATION, 2019, 99
  • [39] Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer
    Stocker, Albina
    Trojan, Andreas
    Elfgen, Constanze
    Hilbers, Marie-Louis
    Moskovszky, Linda
    Varga, Zsuzsanna
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (02) : 311 - 319
  • [40] HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
    Zhao, Jing
    Krishnamurti, Uma
    Zhang, Chao
    Meisel, Jane
    Wei, Zhimin
    Suo, Aili
    Aneja, Ritu
    Li, Zaibo
    Li, Xiaoxian
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (11)
12345